Key result
Gemcitabine plus paclitaxel yields a 27% overall response rate in advanced soft-tissue sarcoma.
Why the study?
A limited number of chemotherapeutic agents have been found to be active against advanced soft-tissue sarcomas, especially after progression following doxorubicin treatment.
Does gemcitabine in combination with paclitaxel improve response and survival in patients with advanced non-resectable soft-tissue sarcomas?
Cohort (n=30)
No
Does gemcitabine in combination with paclitaxel improve response and survival in patients with advanced non-resectable soft-tissue sarcomas?
Gemcitabine plus paclitaxel is a tolerable and effective treatment option for patients with advanced non-resectable soft-tissue sarcomas.
Gemcitabine-paclitaxel may offer benefit in advanced STS; hypothesis-generating and requires randomized confirmation before practice change.
A limited number of chemotherapeutic agents have been found to be active against advanced soft‑tissue sarcomas (STSs), particularly sarcomas that have progressed following doxorubicin treatment. The aim of this retrospective study was to determine the response to treatment with gemcitabine plus paclitaxel in patients with STSs. data were collected on all patients with advanced non‑resectable STS who were treated with a fixed dose 700 mg/m2 gemcitabine in combination with 70 mg/m2 paclitaxel on days 1 and 8 every 3 weeks. A total of 30 patients were included, with a median age of 56.4 years (range, 40‑70 years). The gemcitabine/paclitaxel combination was well tolerated, with an overall response in 27% and a clinical benefit in 57% of the patients. The median progression‑free survival was 6.1 months and the overall survival was 14.3 months. In conclusion, gemcitabine plus paclitaxel was found to be tolerable and effective in patients with advanced STSs.
No takes yet. Share an insight, caveat, or question.
Sonnenblick et al. (2015) conducted a cohort in Advanced soft-tissue sarcomas (n=30). Gemcitabine and paclitaxel was evaluated on Overall response rate. Gemcitabine in combination with paclitaxel achieved an overall response rate of 27% and a clinical benefit rate of 57% in patients with advanced soft-tissue sarcomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: